FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311201797> ?p ?o ?g. }

• W4311201797 endingPage "1102" @default.
• W4311201797 startingPage "1092" @default.
• W4311201797 abstract "Nelarabine, an antimetabolite prodrug, is approved as monotherapy for children and adults with relapsed and refractory T-cell acute lymphoblastic leukemia and lymphoma (R/R T-ALL/LBL), although it is often used in combination regimens. We sought to understand differences in efficacy and toxicity when nelarabine is administered alone or in combination. We retrospectively analyzed 44 consecutive patients with R/R T-ALL/LBL; 29 of whom were treated with combination therapy, most with cyclophosphamide and etoposide (23, 79%) and 15 with monotherapy. The median age was 19 years (range, 2-69), including 18 children (<18 years). After a median of 1 (range, 1-3) cycle of treatment, 24 patients (55%) achieved complete remission, 62% (18/29) with combination therapy and 40% (6/15) with monotherapy (P = .21). Most responders (21, 88%) pursued allogeneic stem cell transplant (alloSCT). Overall survival (OS) was 12.8 months (95% confidence interval, 6.93-not reached) in the entire cohort and was higher in the combination therapy than in the monotherapy group (24-month OS, 53% vs 8%; P = .003). The rate of neurotoxicity was similar between groups (27% vs 17%; P = .46) and grade 3/4 anemia and thrombocytopenia were more frequent in the combination group (76% vs 20%; P < .001% and 66% vs 27%; P = .014, respectively). In a multivariate analysis, nelarabine combination therapy and alloSCT post nelarabine were associated with improved OS (hazard ratio, 0.41; P = .04 and hazard ratio, 0.25; P = .008, respectively). In conclusion, compared with monotherapy, nelarabine combination therapy was well tolerated and associated with improved survival in pediatric and adult patients with R/R T-ALL/LBL." @default.
• W4311201797 created "2022-12-24" @default.
• W4311201797 creator A5003947352 @default.
• W4311201797 creator A5009387581 @default.
• W4311201797 creator A5023296232 @default.
• W4311201797 creator A5036283202 @default.
• W4311201797 creator A5037008808 @default.
• W4311201797 creator A5048748466 @default.
• W4311201797 creator A5049059619 @default.
• W4311201797 creator A5061569936 @default.
• W4311201797 creator A5062404815 @default.
• W4311201797 creator A5071023119 @default.
• W4311201797 creator A5082924494 @default.
• W4311201797 creator A5084266744 @default.
• W4311201797 creator A5088473676 @default.
• W4311201797 date "2023-03-29" @default.
• W4311201797 modified "2023-09-27" @default.
• W4311201797 title "Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia" @default.
• W4311201797 cites W13741693 @default.
• W4311201797 cites W1641010126 @default.
• W4311201797 cites W1831821249 @default.
• W4311201797 cites W1976767488 @default.
• W4311201797 cites W1977380325 @default.
• W4311201797 cites W1991343198 @default.
• W4311201797 cites W2010729137 @default.
• W4311201797 cites W2026450884 @default.
• W4311201797 cites W2049443129 @default.
• W4311201797 cites W2052739233 @default.
• W4311201797 cites W2052846308 @default.
• W4311201797 cites W2060824604 @default.
• W4311201797 cites W2061585822 @default.
• W4311201797 cites W2065077038 @default.
• W4311201797 cites W2104722860 @default.
• W4311201797 cites W2105908490 @default.
• W4311201797 cites W2115482777 @default.
• W4311201797 cites W2132814495 @default.
• W4311201797 cites W2152588250 @default.
• W4311201797 cites W2166306614 @default.
• W4311201797 cites W2418819004 @default.
• W4311201797 cites W2547989191 @default.
• W4311201797 cites W255003803 @default.
• W4311201797 cites W2580322451 @default.
• W4311201797 cites W2617763104 @default.
• W4311201797 cites W2765615779 @default.
• W4311201797 cites W2767124204 @default.
• W4311201797 cites W2781552270 @default.
• W4311201797 cites W2908746540 @default.
• W4311201797 cites W2947201740 @default.
• W4311201797 cites W2969862977 @default.
• W4311201797 cites W2978348183 @default.
• W4311201797 cites W2990689630 @default.
• W4311201797 cites W3037299043 @default.
• W4311201797 cites W3063038225 @default.
• W4311201797 cites W3102538166 @default.
• W4311201797 cites W3108211592 @default.
• W4311201797 cites W3113653584 @default.
• W4311201797 cites W3131213086 @default.
• W4311201797 cites W3212135775 @default.
• W4311201797 doi "https://doi.org/10.1182/bloodadvances.2022008280" @default.
• W4311201797 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36508268" @default.
• W4311201797 hasPublicationYear "2023" @default.
• W4311201797 type Work @default.
• W4311201797 citedByCount "1" @default.
• W4311201797 countsByYear W43112017972023 @default.
• W4311201797 crossrefType "journal-article" @default.
• W4311201797 hasAuthorship W4311201797A5003947352 @default.
• W4311201797 hasAuthorship W4311201797A5009387581 @default.
• W4311201797 hasAuthorship W4311201797A5023296232 @default.
• W4311201797 hasAuthorship W4311201797A5036283202 @default.
• W4311201797 hasAuthorship W4311201797A5037008808 @default.
• W4311201797 hasAuthorship W4311201797A5048748466 @default.
• W4311201797 hasAuthorship W4311201797A5049059619 @default.
• W4311201797 hasAuthorship W4311201797A5061569936 @default.
• W4311201797 hasAuthorship W4311201797A5062404815 @default.
• W4311201797 hasAuthorship W4311201797A5071023119 @default.
• W4311201797 hasAuthorship W4311201797A5082924494 @default.
• W4311201797 hasAuthorship W4311201797A5084266744 @default.
• W4311201797 hasAuthorship W4311201797A5088473676 @default.
• W4311201797 hasBestOaLocation W43112017971 @default.
• W4311201797 hasConcept C126322002 @default.
• W4311201797 hasConcept C141071460 @default.
• W4311201797 hasConcept C143998085 @default.
• W4311201797 hasConcept C207103383 @default.
• W4311201797 hasConcept C2776694085 @default.
• W4311201797 hasConcept C2776999253 @default.
• W4311201797 hasConcept C2778119113 @default.
• W4311201797 hasConcept C44249647 @default.
• W4311201797 hasConcept C71924100 @default.
• W4311201797 hasConcept C90924648 @default.
• W4311201797 hasConceptScore W4311201797C126322002 @default.
• W4311201797 hasConceptScore W4311201797C141071460 @default.
• W4311201797 hasConceptScore W4311201797C143998085 @default.
• W4311201797 hasConceptScore W4311201797C207103383 @default.
• W4311201797 hasConceptScore W4311201797C2776694085 @default.
• W4311201797 hasConceptScore W4311201797C2776999253 @default.
• W4311201797 hasConceptScore W4311201797C2778119113 @default.
• W4311201797 hasConceptScore W4311201797C44249647 @default.
• W4311201797 hasConceptScore W4311201797C71924100 @default.

• next